Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
neutral-positive
2 days agoSwiss giant Novartis to buy Avidity Biosciences in US$12 billion biotech deal
Novartis announced its plan to acquire U.S. biotech firm Avidity Biosciences in a deal valued at roughly US$12 billion, making it the largest takeover under CEO Vas Narasimhan. Novartis shares fell about 1% on the news, while Avidity’s stock surged. The acquisition underscores consolidation in the RNA-based therapeutics area and highlights high valuations in biotechnology. Analysts say integration risk is non-trivial, but the deal reflects the premium placed on next-generation therapies and biotech innovation pipelines.
Explore:Mutual Fund AI Screening
neutral-positive
2 days agoSwiss giant Novartis to buy Avidity Biosciences in US$12 billion biotech deal
Novartis announced its plan to acquire U.S. biotech firm Avidity Biosciences in a deal valued at roughly US$12 billion, making it the largest takeover under CEO Vas Narasimhan. Novartis shares fell about 1% on the news, while Avidity’s stock surged. The acquisition underscores consolidation in the RNA-based therapeutics area and highlights high valuations in biotechnology. Analysts say integration risk is non-trivial, but the deal reflects the premium placed on next-generation therapies and biotech innovation pipelines.
Explore:Mutual Fund AI Screening
neutral-positive
Swiss giant Novartis to buy Avidity Biosciences in US$12 billion biotech deal
3 days ago
1 min read
75 words
Novartis to acquire Avidity Biosciences for US$12 billion; acquirer’s stock dips, target soars on biotech pipeline bet.
Novartis announced its plan to acquire U.S. biotech firm Avidity Biosciences in a deal valued at roughly US$12 billion, making it the largest takeover under CEO Vas Narasimhan. Novartis shares fell about 1% on the news, while Avidity’s stock surged. The acquisition underscores consolidation in the RNA-based therapeutics area and highlights high valuations in biotechnology. Analysts say integration risk is non-trivial, but the deal reflects the premium placed on next-generation therapies and biotech innovation pipelines.
Novartis announced its plan to acquire U.S. biotech firm Avidity Biosciences in a deal valued at roughly US$12 billion, making it the largest takeover under CEO Vas Narasimhan. Novartis shares fell about 1% on the news, while Avidity’s stock surged. The acquisition underscores consolidation in the RNA-based therapeutics area and highlights high valuations in biotechnology. Analysts say integration risk is non-trivial, but the deal reflects the premium placed on next-generation therapies and biotech innovation pipelines.
Tags:
stocks
global
stocks
global
healthcare
mergers & acquisitions
biotech
Oct 27, 2025 • 21:28 IST